Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged

Nov 8, 2024 · While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData By Kevin Dunleavy Nov 8, 2024 5:00am market cap Novo Nordisk Eli Lilly …

CouponFollow Extension

5%
OFF

As Sales Soared Industry-wide In Q3, Pfizer Moved Into Top Spot

4 weeks from now

Nov 25, 2024 · While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData. As for behemoth Johnson & Johnson, it had a sales increase of 5% in the …

fiercepharma.com

2%
OFF

BMS, Gilead And Sanofi Lead Q3 2024 Market Cap Growth

4 weeks from now

Nov 11, 2024 · The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol Myers Squibb, Gilead Sciences and Sanofi stood …

emjreviews.com

2%
OFF

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25

4 weeks from now

Nov 8, 2024 · The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite …

benzinga.com

20%
OFF

Pharmaceutical Giants Eli Lilly And Novo Nordisk Face Challenges ...

4 weeks from now

Nov 8, 2024 · Eli Lilly and Novo Nordisk reported mixed Q3 2024 financial results: Eli Lilly's revenue increased 20% to $11.4 billion, driven by strong sales of Mounjaro and Zepbound, but …

talk.bio

2%
OFF

Top 20 Biopharmas’ Market Cap Rises 2% In Q3 2024 Amid Flurry Of …

4 weeks from now

Nov 6, 2024 · Bristol Myers Squibb (BMS) witnessed the largest growth in market capitalisation of 24.6% to $105bn in Q3 2024, fuelled by robust pipeline progress and the US Food and Drug …

pharmaceutical-technology.com

25%
OFF

Bristol-Myers Squibb Leads Biopharma Recovery With Market Cap …

4 weeks from now

Nov 9, 2024 · Innovate with Unique Financial Content Bristol-Myers Squibb leads biopharma recovery with market cap growth of nearly 25%, but Novo Nordisk and Lilly suffer market …

financialserviceslife.com

2%
OFF

BMS Q3 Drug Sales: Surge In New Products, Dip In Revlimid

4 weeks from now

Oct 26, 2023 · Overall, BMS raked in $10.96 billion in revenue for Q3, reflecting a 2% dip from the same period last year, largely as a result of flagging demand for Revlimid. In terms of full-year …

pharmaceuticalprocessingworld.com

8%
OFF

Why Novo Nordisk Stock Got Destroyed Today, But Eli Lilly And …

4 weeks from now

Dec 20, 2024 · As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece. Novo Nordisk's no good, very bad day

fool.com

2%
OFF

BMS Reports 2% Revenue Loss In 2023 After Revlimid Generics Hurt …

4 weeks from now

Feb 2, 2024 · Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses. ... Q3 2024 update: ecommerce related …

pharmaceutical-technology.com

38%
OFF

Eli Lilly Vs Novo Nordisk: A Recent Study Suggests This Company …

4 weeks from now

Aug 3, 2024 · Eli Lilly (LLY-1.38%) and Novo Nordisk (NVO-0.32%) are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from …

fool.com

25%
OFF

Lilly, GSK, Gilead Outsourced The Most In Q3: Report

4 weeks from now

Oct 27, 2016 · Eli Lilly, GlaxoSmithKline and Gilead outsourced more research work than their pharmaceutical peers in the ... Nearly 25% of the roughly 3,300 clinical trials that took place …

biopharmadive.com

6%
OFF

Bristol-Myers Squibb Leads Biopharma Recovery With Almost

4 weeks from now

Nov 8, 2024 · Bristol-Myers Squibb & Co BMY led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by …

tradingview.com

38%
OFF

Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks

4 weeks from now

Feb 6, 2024 · Novo Nordisk said that sales in its diabetes and obesity care business surged by 38% from a year ago. ... estimates while Lilly has a forward P/E of almost 60 times this year’s …

businessinsider.com

FAQs about Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged Coupon?

Does Novo Nordisk have a lead on Lilly in GLP-1 market share?

Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, research suggests that GLP-1 drugs have applications outside of weight loss. ...

Should Eli Lilly separate from Novo Nordisk?

Such patience could be a wise move in the long run as Mounjaro and Zepbound become more popular. Where Eli Lilly starts to really separate itself from Novo Nordisk is in other markets. For example, over the summer Lilly's Alzheimer's drug received approval from the FDA. ...

Should you buy Novo Nordisk or Lilly?

While Novo Nordisk and Lilly each carry encouraging prospects, I see one of these companies as the superior opportunity. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. ...

Should Novo Nordisk & Eli Lilly be a trillion-dollar stock?

So, it appears that both Novo Nordisk and Eli Lilly should continue to benefit from the strong investor and consumer appetite (pardon the pun) for weight loss drugs. Still, traders need to recognize some of the risks that the companies face on the road to a trillion-dollar valuation. ...

Could a GLP-1 drug be a catalyst for Lilly & Novo Nordisk?

Specifically, research suggests that GLP-1 drugs have applications outside of weight loss. Such areas include sleep apnea, arthritis, kidney disease, cardiovascular disease, and Alzheimer's. Although becoming a multi-platform breakthrough could serve as a catalyst for both Novo Nordisk and Lilly, I think Novo Nordisk has the edge for now. ...

Could a multi-platform breakthrough be a catalyst for Novo Nordisk & Lilly?

Although becoming a multi-platform breakthrough could serve as a catalyst for both Novo Nordisk and Lilly, I think Novo Nordisk has the edge for now. Back in March, Wegovy received an expanded indication from the Food and Drug Administration (FDA) to treat obesity care patients who are also at risk of major cardiovascular events. ...